ImetelChat

BP - Opus 5 came up with the same percentage as Opus 4.8. At this point I think we need new info. The new version was not particularly sharper than the older version.

Yesterday we had the most users ever online - interesting - I wonder why?

Catch a big one BP

Ryan, I'm sure there is absolutely no way that we can know all of the inputs that will be used to determine the IDMC's decision, so every projection is at best a guess. OTH, there seems to be a tacit assumption that the odds for a halt based on efficacy are extremely low - usually quoted around 10 ...

STA - Claude's response:


This is a genuinely sharp point, and it's the *correct* rebuttal to the trial-boost argument we were just discussing — it actually closes a loop. Let me work through it, because the commenter has identified something real.

**What "Secret Third Arm" is pointing at:**

The ...

My Claude's response to Karenna's Claude on Seeking Alpha:

This is worth engaging seriously, because that Claude makes one genuinely correct point that I should concede, one point that's overstated, and one outright error — and the net effect on the number is smaller than its 35-40% suggests. Let ...

Ryan - I did the same thing - I gave ChatGPT the same report and it had a similar first response to your ChatGPT. I then asked Chat to take a deeper dive on a couple of issues and it dramatically changed it's position (my questions did not lead or mislead). So I gave my Chat your Chat's response and ...

8. What We Do Not Know

The integrity of this analysis depends on naming its limits. Each item below is a genuine unknown, left empty of speculation.
8.1 Blinded outcomes (unknowable until readout)
The true randomized hazard ratio — the single governing variable. All estimates rest on a matched ...

7. Consequences of Each Branch

The outcomes differ not only in probability but in what follows. This section maps the downstream path of each terminal branch.

7.1 Branch A — Interim halt for efficacy
The trial stops; control patients may cross to imetelstat; Geron files for registration in R/R MF ...

6. Timeline and the Calendar of Resolution
The interim is event-driven — triggered by ~112 deaths, not a date. Current guidance (reaffirmed at the Q1 2026 earnings call, May 2026, with explicit “at this time” hedging) places the interim in H2 2026 and the final base case in H2 2028.

6.1 The ...

5. Probability Synthesis
Integrating the HR distribution (Section 3.4) with the conditional outcome profiles (Section 4.2) yields the headline probabilities.

5.1 The composite calculation
Weighting each HR band by its probability and its conditional outcome:
Quantity Estimate Confidence
P(true HR ...

4. The Complete Outcome Tree

The HR distribution now maps onto outcomes. The trial has two decision points — the interim (~H2 2026) and the final (~H2 2028) — producing four terminal branches plus their sub-paths.

4.1 The branch structure
Branch Trigger Consequence
A. Interim halt for efficacy ...

3. The Effect Size: Triangulating the Hazard Ratio
With the control arm constrained, the analysis turns to the magnitude of imetelstat’s benefit. Three independent lines converge.

3.1 The matched clinical anchor
The best available estimate is the Kuykendall 2026 matched analysis: imetelstat ...

2 . The Control Arm: Why It Cannot Be Rescued

The greatest threat to the thesis is the possibility that contemporary BAT patients live far longer than the historical 12–16 month benchmark, narrowing the gap. Recent real-world data show post-ruxolitinib survival rising to 34–40 months. Resolving ...

1 . The Governing Variable

Every outcome of IMpactMF is a function of one quantity: the true hazard ratio between the imetelstat and BAT arms. The hazard ratio is the proportional difference in the rate of death between the arms; an HR of 0.50 means imetelstat patients die at half the rate of BAT ...

As many of the readers of this board know - I have been working with Claude to try to get a very good understanding of the potential outcomes of the IMPactMF trial. This process has been on going for several weeks and I think we have reviewed most if not all of the public data on this subject ...

Continued:

The deeper read, which the biology supports and which favors the thesis: The modern regimen delivers patients to the point of failure with more intact marrow — and a disease-modifying drug's leverage is greatest precisely when there is more functioning marrow left to preserve. This is ...

BP, I thought that we hadn't given the new Rux Regime enough attention since it is one of the most likely reasons why the trial is lasting longer so I asked Claude to do a deep dive - this is the result:

Claude responded: This is the right thing to go deep on, because the modern-ruxolitinib-regimen ...

BP — your two points together actually tighten the timing argument rather than weakening it, and I think they resolve the trap you flagged. Here's how I'd put it.

You're right that the delay can't be casually attributed to drug effect, because the early slippage was clearly enrollment-driven. That ...

BP, I used 11/23. My last epiphany was that the original Final Date was projected for the first half of 2026. So our interim date is further out than the original Final date -plenty of time to show separation. There really can't be much of an argument for extending the trial if the stats are in ...